Given the exquisite sensitivity of IDH-mutated AML to venetoclax combinations, and the ability to target other cooperating mutations or clones susceptible to BCL2 inhibition in this AML subtype, we favor using the combination of a hypomethylating agent with venetoclax in patients above the age of 65, able to tolerate this therapy. Here, BCL2 is linked to acute myeloid leukemia.